Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

J Motzer, Robert; Jonasch, Eric; Agarwal, Neeraj; Alva, Ajjai; Baine, Michael; Beckermann, Kathryn; I Carlo, Maria; K Choueiri, Toni; A Costello, Brian; H Derweesh, Ithaar; Desai, Arpita; Ged, Yasser; George, Saby; L Gore, John; Haas, Naomi; L Hancock, Steven; Kapur, Payal; Kyriakopoulos, Christos; T Lam, Elaine; N Lara, Primo; Lau, Clayton; Lewis, Bryan; C Madoff, David; Manley, Brandon; Dror Michaelson, M; Mortazavi, Amir; Nandagopal, Lakshminarayanan; R Plimack, Elizabeth; Ponsky, Lee; Ramalingam, Sundhar; Shuch, Brian; L Smith, Zachary; Sosman, Jeffrey; A Dwyer, Mary; A Gurski, Lisa; Motter, Angela

doi:10.6004/jnccn.2022.0001

Public

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Published in Journal of the National Comprehensive Cancer Network : JNCCN • Jan 1, 2022

NobleIDNI1P06W03R68S50

Authors:

Robert J Motzer

,

Eric Jonasch

,

Neeraj Agarwal

Abstract

The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is importan...

Discussions